4.2 Review

The Role of the PI3K-AKT Pathway in Melanoma

Journal

CANCER JOURNAL
Volume 18, Issue 2, Pages 142-147

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31824d448c

Keywords

Melanoma; PI3K; AKT; PTEN; targeted therapy

Categories

Funding

  1. American Society of Clinical Oncology
  2. Melanoma Research Alliance
  3. GlaxoSmithKline
  4. Genentech
  5. AstraZeneca
  6. Merck
  7. Myriad

Ask authors/readers for more resources

The PI3K (phosphatidylinositol 3-kinase)-AKT pathway is one of the most important signaling networks in cancer. There is growing evidence that activation of this pathway plays a significant role in melanoma, frequently in the setting of concurrent activation of RAS-RAF-MEK-ERK signaling. This evidence includes the identification of genetic and epigenetic events that activate this pathway in melanoma cell lines and clinical specimens. In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance. The availability of many inhibitors against the PI3K-AKT pathway is rapidly leading to the development of trials that will ultimately determine its clinical significance in this disease. The rational development of such therapies will be facilitated by strategies that utilize the growing understanding of the complexity of the regulation and roles of this pathway.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available